CAESAREA, Israel, May 17, 2017 /PRNewswire/ -- DarioHealth Corp.
(NASDAQ: DRIO), a leading global digital health company with mobile
health and big data solutions, today announced that it signed
global life sciences and consumer health executive, Olivier Jarry, to a Strategic Advisory role.
Having managed innovation at the crossroads of technology,
healthcare, and patient-centricity for three decades on five
continents, Mr. Jarry brings a wealth of experience to
DarioHealth.
Mr. Jarry was tapped for this position specifically because he
has made key impacts in executive roles at companies like Bayer
Diabetes, Bristol-Myers Squibb, and Novartis. In addition, he also
serves as an advisor at Fit4D, a company that empowers people with
diabetes to live towards optimal health.
DarioHealth is an integrated care company currently focusing on
diabetes. Today's appointment allows DarioHealth to pursue
additional avenues that will focus on improving better clinical
outcomes for its users.
Erez Raphael, Chairman and CEO of
DarioHealth, commented about the appointment, "Mr. Jarry has over
30 years of experience in improving health and living standards for
people throughout the world. DarioHealth is dedicated to helping
people with diabetes and Mr. Jarry compliments our advisory team.
We look forward to working with him to capitalize on his vast
knowledge ranging from big data techniques to developing new
products and opportunities with added-value."
Olivier Jarry said, "DarioHealth
has a unique, user-centric digital solution that attracts and
retains people who want to better manage their chronic condition.
There is no doubt that the market will transform from pure
monitoring to integrated care, and DarioHealth is at the forefront
of this tectonic shift. I believe that DarioHealth has the right
solution and will apply it to the broader diabetes management
ecosystem."
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company
serving tens of thousands of users with dynamic mobile health
solutions. We believe people deserve the best tools to manage their
treatment, and harnessing big data, we have developed a unique way
for our users to analyze and personalize their diabetes management.
With our smart diabetes solution, users have direct access to track
and monitor all facets of diabetes, without having the disease slow
them down. The acclaimed Dario™ Blood Glucose Monitoring System
all-in-one blood glucose meter and native smartphone app gives
users an unrivaled method for self-diabetes management. DarioHealth
is headquartered in Caesarea,
Israel with a regional office in Burlington, Massachusetts. For more
information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company
describes the impact of Mr. Jarry's appointment, and that the
market will transform from pure monitoring to integrated care, it
is using forward-looking statements. Readers are cautioned
that certain important factors may affect the Company's actual
results and could cause such results to differ materially from any
forward-looking statements that may be made in this news release.
Factors that may affect the Company's results include, but are not
limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
shmuel@mydario.com
1-800-896-9062
DarioHealth Investor Relations Contact
Hayden IR
Rob Fink / Brett Maas
DRIO@HaydenIR.com
646-415-8972 / 646-536-7331
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dariohealth-adds-former-bayer-diabetes-executive-and-visionary-to-its-advisory-board-300459185.html
SOURCE DarioHealth Corp.